達仁堂(600329.SH):上半年淨利潤19.28億元 同比增長193.08%
格隆匯8月14日丨達仁堂(600329.SH)公佈半年度報告,2025年上半年,公司實現營業收入26.51億元,由於在2024年末公司將旗下全資子公司天津中新醫藥有限公司的全部股權作價,以增資形式併入津藥太平醫藥有限公司,醫藥商業板塊從公司合併範圍內剝離,今年不再確認其收入,導致中期收入同比下降。本報告期公司工業主營收入26.45億元,同比增長0.87%。上半年,公司實現歸屬於母公司股東的淨利潤19.28億元,同比增長193.08%,主要是由於轉讓中美天津史剋制藥有限公司(簡稱“天津史克”)12%的股權實現稅後淨收益13.08億元,歸屬於上市公司股東的扣除非經常性損益的淨利潤5.96億元,同比下降5.93%,主要是自去年年末至本報告期內兩次出售了持有聯營公司天津史克25%的股權,本期不再確認其聯營公司投資收益,而同期包含天津史克聯營公司投資收益1.06億元。扣除該聯營公司投資收益影響後,歸屬於母公司所有者的扣除非經常性損益的淨利潤同比增加12.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.